- Home
- EXTR vs HRMY Comparison
EXTR vs HRMY Comparison
Compare EXTR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXTR | HRMY |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXTR | HRMY |
|---|---|---|
| Price | $16.94 | $40.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $21.80 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 1.2M | 789.9K |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | 0.06 | ★ 3.17 |
| Revenue | ★ $1,181,108,000.00 | $825,944,000.00 |
| Revenue This Year | $12.45 | $23.11 |
| Revenue Next Year | $7.33 | $16.15 |
| P/E Ratio | $283.21 | ★ $12.79 |
| Revenue Growth | 14.31 | ★ 21.13 |
| 52 Week Low | $10.10 | $25.52 |
| 52 Week High | $22.89 | $40.93 |
Technical Indicators
Market Signals| Indicator | EXTR | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 80.09 |
| Support Level | $16.99 | $38.12 |
| Resistance Level | $18.36 | $40.00 |
| Average True Range (ATR) | 0.46 | 1.20 |
| MACD | 0.10 | 0.25 |
| Stochastic Oscillator | 7.33 | 100.00 |
Price Performance
Historical ComparisonAbout EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.